Document Detail


Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
MedLine Citation:
PMID:  22890275     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Therapy with tumour necrosis factor α (TNF) inhibitors can be associated with paradoxical reactions, namely the de novo development or flaring of conditions that usually respond to these therapeutic agents, such as arthritis, inflammatory bowel disease, sarcoidosis or psoriasis. They are considered a class effect of these drugs, and their incidence ranges from 1 to 5%, with paradoxical psoriasis (psoriasis vulgaris, palmoplantar pustulosis, scalp psoriasis and their combinations) being most frequently reported. Treatment of paradoxical psoriasis often requires withdrawal of the inducing drug and switching to another anti-TNF agent, but often this cannot avoid recurrence or persistence of the rash and/or loss of the therapeutic effect on the underlying condition.
CASE REPORT: We report on a 47-year-old woman who developed incapacitating palmoplantar pustulosis and psoriasis vulgaris flare with severe scalp and nail involvement after 5 months of treatment with adalimumab for psoriatic arthritis. Several treatments, including topical corticosteroids, photochemotherapy, ciclosporin, acitretin and etanercept 50 mg twice a day for 1 month, were ineffective or not tolerated. Treatment with ustekinumab 45 mg provided complete resolution of skin lesions with acceptable therapeutic control of the arthritis, with a follow-up duration of 16 months.
CONCLUSION: A review of the reported cases suggests that this may be a therapeutic option in patients who develop paradoxical psoriasis while under treatment for arthritis or Crohn's disease.
Authors:
Lluís Puig; Caridad E Morales-Múnera; Anna López-Ferrer; Carme Geli
Related Documents :
18417985 - Fetal cardiocentesis: a review of indications, risks, applications and technique.
1606565 - Trisomy 4 in acute nonlymphocytic leukemia. report of two cases and review of the liter...
15549335 - Study of abdominal circumference proportions in fetuses with growth disorders.
9147875 - A history of miscarriages and mild prognathism as possible mode of presentation of mosa...
20503065 - Primary skull-based yolk-sac tumour: case report and review of central nervous system g...
20529415 - Olfactory reference syndrome: a systematic review of the world literature.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2012-08-10
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  225     ISSN:  1421-9832     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-18     Completed Date:  2013-03-26     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  14-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. lpuig@santpau.cat
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / adverse effects*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects*
Arthritis, Psoriatic / drug therapy*
Drug Eruptions / drug therapy*,  etiology
Female
Humans
Middle Aged
Psoriasis / chemically induced
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; FU77B4U5Z0/ustekinumab; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-throughput fractionation of human plasma for fast enrichment of low- and high-abundance protein...
Next Document:  Long-range inhibitory mechanisms in the visual system are impaired in migraine sufferers.